Improved Detection of Bladder Cancers with Cysview
Smilow Cancer Hospital is one of the only hospitals in Connecticut to offer Blue Light Cystoscopy with Cysview, which has been proven to significantly increase the detection of bladder cancer over white-light cystoscopy alone. In fact, 20.7% of patients with primary bladder cancer has had at least one tumor detected with blue light that was not detected when using white light. And 27.7% of patients with recurrent bladder cancer had at least one tumor detected with blue light that was not detected with white light, and a seven-month improvement in time to recurrence has been demonstrated.
Following diagnosis, the multidisciplinary bladder cancer team offers our patients complete care with specialized pathology, neoadjuvant therapy options, an enhanced recovery after surgery (ERAS) protocol, which has been demonstrated to reduce the length of stay and post-surgical complications, as well as advanced surgical techniques to maintain sexual function and bladder control.
Learn more about Cysview here.
About Bladder Cancer
- Transitional cell carcinoma – Transitional cell carcinoma originates from the bladder’s inner lining or urothelium and is the most common form of bladder cancer.
- Squamous cell carcinoma – This type of bladder cancer involves the thin, flat cells of the bladder. This form of bladder cancer is not as common in the United States.
- Adenocarcinoma – Adenocarcinoma originates in the cells that release mucus and other fluids. It can also originate from remnants of the umbilical cord.